Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02449447
Other study ID # E-compared
Secondary ID
Status Completed
Phase N/A
First received March 30, 2015
Last updated September 19, 2017
Start date February 2015
Est. completion date June 2017

Study information

Verified date September 2017
Source Linkoeping University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To asses the clinical effectiveness of blended cognitive behavior therapy (CBT): face-to-face and internet-based treatment for adults with Major Depressive Disorder (MDD) in primary care compared to treatment as usual.


Description:

The study is part of a EU-project. Participants are recruited via regular routes from primary care settings. Following the Mini International Neuropsychiatric Interview (M.I.N.I.) participants will be randomly allocated to either blended treatment for 10 sessions/weeks or to treatment as usual. We will include 150 participants in total.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date June 2017
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- depressive symptoms according to DSM-IV

- have access to a computer with internet connection

- have good knowledge of the Swedish language

Exclusion Criteria:

- recent (during last 6 weeks) change in psychiatric medication

- presently in any other psychological treatment

- severe depression

- suicidal ideation

Study Design


Intervention

Behavioral:
Cognitive behavioral therapy
CBT based on behavioral activation and cognitive therapy techniques including homework
Other:
Treatment as usual
Treatment as usual in primary care including antidepressants and counselling

Locations

Country Name City State
Sweden Department of Behavioral Sciences and Learning, Linköping University Linköping Östergötland

Sponsors (2)

Lead Sponsor Collaborator
Linkoeping University European Commission

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quick Inventory of Depressive Symptomatology Self-Report (QIDS Symptoms of depression measured by the QIDS. The QIDS is a questionnaire that screens for depressive symptoms and assesses depression severity. Change from baseline in symptoms of depression. Time Frame: 0, 3, 6 and 12 months
Secondary EuroQol-5D (EQ-5D-5L) Quality of life will be assessed with the EQ-5D-5L (EuroQol). The EQ-5D-5L is a self-report questionnaire which measures health related quality of life. Time Frame: 0, 3, 6 and 12 months
Secondary Client Satisfaction Questionnaire (CSQ-8) Patient's satisfaction with the treatment is assessed with Client Satisfaction Questionnaire (CSQ-8) Time Frame: 3 months (post treatment)
Secondary Credibility and Expectancy Questionnaire (CEQ) Patients' expectancy of treatment will be assessed with the credibility and expectancy questionnaire (CEQ) Time Frame: 3 months (post treatment)
Secondary System Usability Scale (SUS) Satisfaction with the internet platform will be evaluated with the system usability scale (SUS) Time Frame: 3 months (post treatment)
Secondary Patient Health Questionnaire (PHQ-9) The PHQ-9 is a nine-item mood module that can be used to screen and to diagnose patients with depressive disorders. Time Frame: 0, 3, 6 and 12 months
Secondary Working Alliance Inventory (WAI-SF) The therapeutic alliance between therapists and patient will be assessed with the short version of the Working Alliance Inventory (WAI-SF). Time Frame: 0 months ( three weeks after started treatment)
Secondary Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness (TIC-P) Health service uptake and production loss due to illness will be measured with the Trimbos and iMTA Questionnaires on Costs Associated with Psychiatric Illness (TiC-P) Time Frame: 0, 3, 6 and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT02972398 - N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders N/A
Completed NCT00855530 - Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder Phase 3
Completed NCT00825019 - Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine Phase 3
Completed NCT02829671 - Loneliness and Occurrence of Suicide Attempts and Suicidal Ideas N/A
Recruiting NCT02681822 - Multi-center Imaging Genetics Studies in China
Completed NCT00825058 - Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine Phase 3
Recruiting NCT04497493 - Efficacy of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Major Depressive Disorder N/A
Completed NCT01347138 - Health Care Management for the Elderly in Community Through Screening N/A
Completed NCT01377896 - The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours N/A
Completed NCT06239740 - Effects of Electroacupuncture on Cognitive Symptoms in Major Depressive Disorder N/A
Not yet recruiting NCT02942251 - Relapse Predicting Model for First Episode Depression N/A
Recruiting NCT02590185 - MetAbolism vaRiability of VEnLafaxine N/A